The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation (ILOFLOW)
Diabetes, Arteriosclerosis, Peripheral Arterial Occlusive Disease
About this trial
This is an interventional treatment trial for Diabetes focused on measuring blood flow volume, ilomedin, measurement, intraarterial, neuropathy
Eligibility Criteria
Inclusion Criteria:
- patients with diabetes and non diabetes
- patients with peripheral artery occlusive disease and who undergo surgical treatment in distal vessels
- spinal anesthesia
- written consent
Exclusion Criteria:
- pregnancy
- heart attack the last 6 months
- stroke the last 6 months
- hypotension
- edema of the lungs
- heart failure
- heart disease
- chronic obstructive pulmonary disease (COPD)
- ulcus ventriculi
- renal disease
- coronary disease
- immaturity
- general anesthesia
Sites / Locations
- Department of vascular and endovascular surgery, Georg Hagmüller Institute for Vascular Research WilhelminenhospitalRecruiting
Arms of the Study
Arm 1
Experimental
Ilomedin, bloodflow volume, measurement,
Surgery was performed under general anesthesia via a longitudinal skin incision. After systemic administration of 5000 IU of unfractionated Heparin, the peripheral vessels were clamped. Following a longitudinal arteriotomy, thrombendarterectomy of the common femoral artery was performed in all cases, extending into the deep femoral artery and superficial femoral artery when necessary. At the end of the reconstruction, 3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were administered into the common femoral artery. Distal to the injection site doppler flow measurement was performed at the common femoral artery prior to arteriotomy, prior to the intraarterial application of iloprost and 5 and 10 minutes afterwards, using the Sono TT FlowLab instrument. During the procedure, systemic arterial blood pressure was continuously documented using a pressure transducer connected to an intraarterial cannula placed in the radial artery of the forearm.